Treatment options in AML have recently expanded with the introduction of immune-conjugates, such as gemtuzumab-ozogamicin (GO) or tagraxofusp, and new targeted molecules; for example FLT3, IDH1, IDH2 and BCL2 inhibitors [1]. The gene discussed is FLT3; the disease is acute myeloid leukemia.